TLR4 and inflammatory bowel disease: These differences further cause interventions effective in animal experiments (e.g., specific probiotics, TLR4 inhibitors) to fail in humans due to “microbiota adaptability” or “pathway activity differences” (e.g., the response rate of human IBD patients to Lactobacillus intervention is only 40%).